Texas Hispanic Journal of Law & Policy

Journal containing articles, notes, book reviews, and other analyses of law and legal cases

PLoS Pathog

Cells employ active measures to restrict infection by pathogens, even prior to responses from the innate and humoral immune defenses. In this context selective autophagy is activated upon pathogen induced membrane rupture to sequester and deliver membrane fragments and their pathogen contents for lysosomal degradation. Adenoviruses, which breach the endosome upon entry, escape this fate by penetrating into the cytosol prior to autophagosome sequestration of the ruptured endosome. We show that virus induced membrane damage is recognized through Galectin-8 and sequesters the autophagy receptors NDP52 and p62. We further show that a conserved PPxY motif in the viral membrane lytic protein VI is critical for efficient viral evasion of autophagic sequestration after endosomal lysis. Comparing the wildtype with a PPxY-mutant virus we show that depletion of Galectin-8 or suppression of autophagy in ATG5-/- MEFs rescues infectivity of the PPxY-mutant virus while depletion of the autophagy receptors NDP52, p62 has only minor effects. Furthermore we show that wildtype viruses exploit the autophagic machinery for efficient nuclear genome delivery and control autophagosome formation via the cellular ubiquitin ligase Nedd4.2 resulting in reduced antigenic presentation. Our data thus demonstrate that a short PPxY-peptide motif in the adenoviral capsid permits multi-layered viral control of autophagic processes during entry

Development of a small compound inhibitor screening against Virus/Host [LP]PxY/Nedd4 interaction as broad spectrum antiviral drug target

L’identification d’antiviraux à large spectre est un des défis majeurs de la rechercheactuelle en virologie. Une des stratégies les plus prometteuses consiste à cibler une interactionvirus/hôte conservée. Ainsi, avec la technique d’AlphaScreen® et le modèle d’interactionprotéine VI de l’Adénovirus (AdV)/Nedd4-2, nous avons réalisé un criblage biochimique àhaut débit contre l’interaction virus/hôte [LP]PxY/Nedd4, commune à différentes familles devirus. Nous avons trouvé des candidats inhibiteurs issus d’une banque de composés approuvéspar les agences de santé. Nous les avons testés, caractérisés et validé leur effet antiviral surdeux familles de virus totalement différentes. Ainsi, les composés C9 (Sulconazole) et C4(Flunarizine) que nous avons identifiés diminuent la réplication de l’AdV, un virus à ADNenveloppé et du virus de Marburg, un virus à ARN, non enveloppé de la famille desFiloviridae. Ces résultats ont permis de valider l’interaction [LP]PxY/Nedd4 comme unecible idéale d’un antiviral à large spectre et de proposer un repositionnement de ces moléculesC9 et C4 comme antiviraux potentiels. Nous avons également synthétisé de nouvellesmolécules analogues du composé C9 et démontré qu’elles étaient tout aussi efficaces que lecomposé lui-même sur la réplication de l’AdV. Ces résultats nous ont permis de présenter laclasse des dérivés imidazolés comme structure de base pour l’élaboration de nouveauxantiviraux, potentiellement à large spectre.Broad-spectrum antiviral identification is considered as one of the major aims of theactual virology research and one strategy consists in targeting virus/host interaction. Using theAlphaScreen® technology and the adenoviral model protein VI/Nedd4-2, we performed highthroughputbiochemical screening targeting the [LP]PxY/Nedd4 interaction, a commoninteraction of different virus families. We identified candidate inhibitors from a librarycompound approved by health agencies. We tested, characterized and validated the antiviraleffect of those compounds on two very different virus families. Indeed, compounds C9(Sulconazole) and C4 (Flunarizine) decrease replication of the adenovirus, a DNA nonenvelopedvirus and the replication of the Marburg virus, an RNA enveloped virus from theFilovirus family. Taken together, those results permit us to validate the [LP]PxY/Nedd4interaction as good target for a broad spectrum antiviral and to propose the “repositioning” ofcompounds C4 and C9 as antivirals. Moreover, we have synthesized new analogues from C9showing similar effect on AdV replication compared to the original molecule (C9). Inconclusion, our work on developing new broad-spectrum antivirals highlights the possibilityto use imidazole derivatives as a new class of antiviral compounds

Criblage d’inhibiteurs de l’interaction virus/hôte [LP]PxY/Nedd4 : une cible antivirale à large spectre

Broad-spectrum antiviral identification is considered as one of the major aims of theactual virology research and one strategy consists in targeting virus/host interaction. Using theAlphaScreen® technology and the adenoviral model protein VI/Nedd4-2, we performed highthroughputbiochemical screening targeting the [LP]PxY/Nedd4 interaction, a commoninteraction of different virus families. We identified candidate inhibitors from a librarycompound approved by health agencies. We tested, characterized and validated the antiviraleffect of those compounds on two very different virus families. Indeed, compounds C9(Sulconazole) and C4 (Flunarizine) decrease replication of the adenovirus, a DNA nonenvelopedvirus and the replication of the Marburg virus, an RNA enveloped virus from theFilovirus family. Taken together, those results permit us to validate the [LP]PxY/Nedd4interaction as good target for a broad spectrum antiviral and to propose the “repositioning” ofcompounds C4 and C9 as antivirals. Moreover, we have synthesized new analogues from C9showing similar effect on AdV replication compared to the original molecule (C9). Inconclusion, our work on developing new broad-spectrum antivirals highlights the possibilityto use imidazole derivatives as a new class of antiviral compounds.L’identification d’antiviraux à large spectre est un des défis majeurs de la rechercheactuelle en virologie. Une des stratégies les plus prometteuses consiste à cibler une interactionvirus/hôte conservée. Ainsi, avec la technique d’AlphaScreen® et le modèle d’interactionprotéine VI de l’Adénovirus (AdV)/Nedd4-2, nous avons réalisé un criblage biochimique àhaut débit contre l’interaction virus/hôte [LP]PxY/Nedd4, commune à différentes familles devirus. Nous avons trouvé des candidats inhibiteurs issus d’une banque de composés approuvéspar les agences de santé. Nous les avons testés, caractérisés et validé leur effet antiviral surdeux familles de virus totalement différentes. Ainsi, les composés C9 (Sulconazole) et C4(Flunarizine) que nous avons identifiés diminuent la réplication de l’AdV, un virus à ADNenveloppé et du virus de Marburg, un virus à ARN, non enveloppé de la famille desFiloviridae. Ces résultats ont permis de valider l’interaction [LP]PxY/Nedd4 comme unecible idéale d’un antiviral à large spectre et de proposer un repositionnement de ces moléculesC9 et C4 comme antiviraux potentiels. Nous avons également synthétisé de nouvellesmolécules analogues du composé C9 et démontré qu’elles étaient tout aussi efficaces que lecomposé lui-même sur la réplication de l’AdV. Ces résultats nous ont permis de présenter laclasse des dérivés imidazolés comme structure de base pour l’élaboration de nouveauxantiviraux, potentiellement à large spectre

Development of a small compound inhibitor screening against Virus/Host [LP]PxY/Nedd4 interaction as broad spectrum antiviral drug target

L’identification d’antiviraux à large spectre est un des défis majeurs de la rechercheactuelle en virologie. Une des stratégies les plus prometteuses consiste à cibler une interactionvirus/hôte conservée. Ainsi, avec la technique d’AlphaScreen® et le modèle d’interactionprotéine VI de l’Adénovirus (AdV)/Nedd4-2, nous avons réalisé un criblage biochimique àhaut débit contre l’interaction virus/hôte [LP]PxY/Nedd4, commune à différentes familles devirus. Nous avons trouvé des candidats inhibiteurs issus d’une banque de composés approuvéspar les agences de santé. Nous les avons testés, caractérisés et validé leur effet antiviral surdeux familles de virus totalement différentes. Ainsi, les composés C9 (Sulconazole) et C4(Flunarizine) que nous avons identifiés diminuent la réplication de l’AdV, un virus à ADNenveloppé et du virus de Marburg, un virus à ARN, non enveloppé de la famille desFiloviridae. Ces résultats ont permis de valider l’interaction [LP]PxY/Nedd4 comme unecible idéale d’un antiviral à large spectre et de proposer un repositionnement de ces moléculesC9 et C4 comme antiviraux potentiels. Nous avons également synthétisé de nouvellesmolécules analogues du composé C9 et démontré qu’elles étaient tout aussi efficaces que lecomposé lui-même sur la réplication de l’AdV. Ces résultats nous ont permis de présenter laclasse des dérivés imidazolés comme structure de base pour l’élaboration de nouveauxantiviraux, potentiellement à large spectre.Broad-spectrum antiviral identification is considered as one of the major aims of theactual virology research and one strategy consists in targeting virus/host interaction. Using theAlphaScreen® technology and the adenoviral model protein VI/Nedd4-2, we performed highthroughputbiochemical screening targeting the [LP]PxY/Nedd4 interaction, a commoninteraction of different virus families. We identified candidate inhibitors from a librarycompound approved by health agencies. We tested, characterized and validated the antiviraleffect of those compounds on two very different virus families. Indeed, compounds C9(Sulconazole) and C4 (Flunarizine) decrease replication of the adenovirus, a DNA nonenvelopedvirus and the replication of the Marburg virus, an RNA enveloped virus from theFilovirus family. Taken together, those results permit us to validate the [LP]PxY/Nedd4interaction as good target for a broad spectrum antiviral and to propose the “repositioning” ofcompounds C4 and C9 as antivirals. Moreover, we have synthesized new analogues from C9showing similar effect on AdV replication compared to the original molecule (C9). Inconclusion, our work on developing new broad-spectrum antivirals highlights the possibilityto use imidazole derivatives as a new class of antiviral compounds

Sliding-strip microfluidic device enables ELISA on paper

This article describes a 3D microfluidic paper-based analytical device that can be used to conduct an enzyme-linked immunosorbent assay (ELISA). The device comprises two parts: a sliding strip (which contains the active sensing area) and a structure surrounding the sliding strip (which holds stored reagents—buffers, antibodies, and enzymatic substrate—and distributes fluid). Running an ELISA involves adding sample (e.g. blood) and water, moving the sliding strip at scheduled times, and analyzing the resulting color in the sensing area visually or using a flatbed scanner. We demonstrate that this device can be used to detect C-reactive protein (CRP)—a biomarker for neonatal sepsis, pelvic inflammatory disease, and inflammatory bowel diseases—at a concentration range of 1-100 ng/mL in 1000-fold diluted blood (1-100 µg/mL in undiluted blood). The accuracy of the device (as characterized by the area under the receiver operator characteristics curve) is 89% and 83% for cut-offs of 10 ng/mL (for neonatal sepsis and pelvic inflammatory disease) and 30 ng/mL (for inflammatory bowel diseases) CRP in 1000-fold diluted blood respectively. In resource limited settings, the device can be used as a part of a kit (containing the device, a fixed-volume capillary, a pre-filled tube, a syringe, and a dropper); this kit would cost ~$0.50 when produced in large scale (>100,000 devices/week). This kit has the technical characteristics to be employed as a pre-screening tool, when combined with other data such as patient history and clinical signs.Chemistry and Chemical Biolog

J Virol

Nuclear delivery of the adenoviral genome requires that the capsid cross the limiting membrane of the endocytic compartment and traverse the cytosol to reach the nucleus. This endosomal escape is initiated upon internalization and involves a highly coordinated process of partial disassembly of the entering capsid to release the membrane lytic internal capsid protein VI. Using wild-type and protein VI-mutated human adenovirus serotype 5 (HAdV-C5), we show that capsid stability and membrane rupture are major determinants of entry-related sorting of incoming adenovirus virions. Furthermore, by using electron cryomicroscopy, as well as penton- and protein VI-specific antibodies, we show that the amphipathic helix of protein VI contributes to capsid stability by preventing premature disassembly and deployment of pentons and protein VI. Thus, the helix has a dual function in maintaining the metastable state of the capsid by preventing premature disassembly and mediating efficient membrane lysis to evade lysosomal targeting. Based on these findings and structural data from cryo-electron microscopy, we suggest a refined disassembly mechanism upon entry. In this study, we show the intricate connection of adenovirus particle stability and the entry-dependent release of the membrane-lytic capsid protein VI required for endosomal escape. We show that the amphipathic helix of the adenovirus internal protein VI is required to stabilize pentons in the particle while coinciding with penton release upon entry and that release of protein VI mediates membrane lysis, thereby preventing lysosomal sorting. We suggest that this dual functionality of protein VI ensures an optimal disassembly process by balancing the metastable state of the mature adenovirus particle

The Amphipathic Helix of Adenovirus Capsid Protein VI Contributes to Penton Release and Postentry Sorting

Nuclear delivery of the adenoviral genome requires that the capsid cross the limiting membrane of the endocytic compartment and traverse the cytosol to reach the nucleus. This endosomal escape is initiated upon internalization and involves a highly coordinated process of partial disassembly of the entering capsid to release the membrane lytic internal capsid protein VI. Using wild-type and protein VI-mutated human adenovirus serotype 5 (HAdV-C5), we show that capsid stability and membrane rupture are major determinants of entry-related sorting of incoming adenovirus virions. Furthermore, by using electron cryomicroscopy, as well as penton- and protein VI-specific antibodies, we show that the amphipathic helix of protein VI contributes to capsid stability by preventing premature disassembly and deployment of pentons and protein VI. Thus, the helix has a dual function in maintaining the metastable state of the capsid by preventing premature disassembly and mediating efficient membrane lysis to evade lysosomal targeting. Based on these findings and structural data from cryo-electron microscopy, we suggest a refined disassembly mechanism upon entry. IMPORTANCE In this study, we show the intricate connection of adenovirus particle stability and the entry-dependent release of the membrane-lytic capsid protein VI required for endosomal escape. We show that the amphipathic helix of the adenovirus internal protein VI is required to stabilize pentons in the particle while coinciding with penton release upon entry and that release of protein VI mediates membrane lysis, thereby preventing lysosomal sorting. We suggest that this dual functionality of protein VI ensures an optimal disassembly process by balancing the metastable state of the mature adenovirus particle

PPxY-mediated endosomal escape prevents autophagic degradation of incoming virions.

<p>(A) Left panel: U2OS cells expressing the Pi3P <i>in cellulo</i> binding probe PX-GFP were treated with vehicle (top) or with 5mM of the Pi3K inhibitor 3’MA (bottom). Middle panel: U2OS cells pre-treated with vehicle alone (black bars) or 3’MA (red bars) were transduced with WT or M1. Transgene expression was determined and normalized to vehicle treated controls to show the fold induction of infectivity upon treatment. Right panel: The same data as in the middle panel showing the level of M1 infectivity rescue compared to the normalized WT infectivity upon treatment. (B) Left panel: U2OS cells were treated with vehicle (top) or with chloroquine (CQ, 50μM, bottom) to block the autophagic flux, fixed and stained for LC3. Middle panel: Cells were treated with vehicle alone (black bars) or chloroquine (red bars) and transduced with WT or M1. Transgene expression was determined and normalized to vehicle treated controls to show the fold induction of infectivity. Right panel: The same data as in the middle panel showing the level of M1 infectivity rescue compared to normalized WT infectivity. (C) Left panel: U2OS cells depleted for ATG5 (SH-ATG5) or control depleted cells (SH-CTRL) and starved using HBSS during 4h, fixed and stained for LC3. Middle panel: Cells were transduced with WT or M1 and the relative transduction efficiency in SH-CTRL cells (black bars) and SH-ATG5 cells (red bars) was determined. Right panel: The same data as in the middle panel showing the level of M1 infectivity rescue compared to normalized WT infectivity. ATG5 expression levels were determined by western blot. (D) Left panel: Control MEFs (ATG5 +/+) and KO MEFs (ATG5 -/-) were transduced with WT or M1 as indicated and the relative transduction efficiency for the M1 (red bars) compared to the WT (black bars) was determined. Right panel: The panel shows the absolute number of transduced cells at indicated amounts of physical particles added to the cell (pp/c) for the WT (black bars) and the M1 (red bars) in ATG5 control (left) and KO (right) MEFs. ATG5 expression levels were determined by western blot.</p